This study tested a new antifungal drug called SF001 against a well-established antifungal called amphotericin B. Researchers tested both drugs against common fungal infections affecting vulnerable patients. SF001 was found to work as well as or better than amphotericin B, particularly against harder-to-treat Aspergillus fungi, while potentially causing fewer side effects.